1.
|
Harries M and Smith I: The development and
clinical use of trastuzumab (Herceptin). Endocr Relat Cancer.
9:75–85. 2002.
|
2.
|
Sáez R, Molina MA, Ramsey EE, et al:
p95HER2 predicts worse outcome in patients with HER2-positive
breast cancer. Clin Cancer Res. 12:424–431. 2006.
|
3.
|
Molina MA, Sáez R, Ramsey EE, et al:
NH2-terminal truncated HER2 protein but not full-length receptor is
associated with nodal metastasis in human breast cancer. Clin
Cancer Res. 8:347–353. 2002.
|
4.
|
Christianson TA, Doherty JK, Lin YJ, et
al: NH2-terminally truncatedHER2/neu protein: relationship with
shedding of the extracellular domain and with prognostic factors in
breast cancer. Cancer Res. 58:5123–5129. 1998.
|
5.
|
Nahta R and Esteva FJ: HER2 therapy:
molecular mechanisms of trastuzumab resistance. Breast Cancer Res.
8:215–222. 2006.
|
6.
|
Fujita T, Doihara H, Kawasaki K, et al:
PTEN activity could be a predictive marker of trastuzumab efficacy
in the treatment of ErbB2-overexpressing breast cancer open. Br J
Cancer. 94:247–252. 2006.
|
7.
|
Nagata Y, Lan KH, Zhou X, et al: PTEN
activation contributes to tumor inhibition by trastuzumab, and loss
of PTEN predicts trastuzumab resistance in patients. Cancer Cell.
6:117–127. 2004.
|
8.
|
Xia W, Husain I, Liu L, et al: Lapatinib
antitumor activity is not dependent upon phosphatase and tensin
homologue deleted on chromosome 10 in ErbB2-overexpressing breast
cancers. Cancer Res. 67:1170–1175. 2007.
|
9.
|
Pérez-Tenorio G, Alkhori L, Olsson B, et
al: PIK3CA mutations and PTEN loss correlate with similar
prognostic factors and are not mutually exclusive in breast cancer.
Clin Cancer Res. 13:3577–3584. 2007.
|
10.
|
Berns K, Horlings HM, Hennessy BT, et al:
A functional genetic approach identifies the PI3K pathway as a
major determinant of trastuzumab resistance in breast cancer.
Cancer Cell. 12:395–402. 2007.
|
11.
|
Toi M, Iwata H, Fujiwara Y, et al:
Lapatinib monotherapy in patients with relapsed, advanced, or
metastatic breast cancer: efficacy, safety, and biomarker results
from Japanese patients phase II studies. Br J Cancer.
101:1676–1682. 2009.
|
12.
|
Xu BH, Jiang ZF, Chua D, et al: Lapatinib
plus capecitabine in treating HER2-positive advanced breast cancer:
efficacy, safety, and biomarker results from Chinese patients. Chin
J Cancer. 30:327–335. 2011.
|
13.
|
Maruyama N, Miyoshi Y, Taguchi T, Tamaki
Y, Monden M and Noguchi S: Clinicopathologic analysis of breast
cancers with PIK3CA mutations in Japanese women. Clin Cancer Res.
13:408–414. 2007.
|
14.
|
Saal LH, Holm K, Maurer M, et al: PIK3CA
mutations correlate with hormone receptors, node metastasis, and
ERBB2, and are mutually exclusive with PTEN loss in human breast
carcinoma. Cancer Res. 65:2554–2559. 2005.
|
15.
|
Scaltriti M, Rojo F, Ocaña A, et al:
Expression of p95HER2, a truncated form of the HER2 receptor, and
response to anti-HER2 therapies in breast cancer. J Natl Cancer
Inst. 99:628–638. 2007.
|
16.
|
Sperinde J, Jin X, Banerjee J, et al:
Quantitation of p95HER2 in paraffin sections by using a
p95HER2-specific antibody and correlation with outcome in a cohort
of trastuzumab-treated breast cancer patients. Clin Cancer Res.
16:42262010.
|
17.
|
Hayashi M, Okumura Y, Osako T, Toyozumi Y,
Arima N, Iwase H and Nishimura R: Time to first tumor progression
as a predictor of efficacy of continued treatment with trastuzumab
beyond progression in human epidermal growth factor
receptor2-positive metastatic breast cancer. Int J Clin Oncol.
16:694–700. 2011.
|
18.
|
Metro G, Giannarelli D, Gemma D, et al:
Time to first tumor progression as outcome predictor of a second
trasuzumab-based therapy beyond progression in HER-2 metastatic
breast cancer. Breast J. 16:66–72. 2010.
|
19.
|
Shousha S: Oestrogen receptor status of
breast carcinoma: Allred/H score conversion table. Histopathology.
53:346–347. 2008.
|
20.
|
Hennessy BT, Gonzalez-Angulo AM,
Stemke-Hale K, et al: Characterization of a naturally occurring
breast cancer subset enriched in epithelial-to-mesenchymal
transition and stem cell characteristics. Cancer Res. 69:4116–4124.
2009.
|
21.
|
Dave B, Migliaccio I, Gutierrez MC, et al:
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase
activation and response to trastuzumab or lapatinib in human
epidermal growth factor receptor 2-overexpressing locally advanced
breast cancers. J Clin Oncol. 29:166–173. 2010.
|
22.
|
Yining S, Weidong H, Yuping T, et al: A
novel proximity assay for the detection of proteins and protein
complexes: quantitation of HER1 and HER2 total protein expression
and homodimerization in formalin-fixed, paraffin-embedded cell
lines and breast cancer tissue. Diagnostic Molecular Pathology.
18:11–21. 2009.
|
23.
|
Loibl S, Bruey J, Von Minckwitz G, et al:
Validation of p95HER2 as a predictive marker for trastuzumab-based
therapy in primary HER2-positive breast cancer: a translational
investigation from the neoadjuvant GeparQuattro study. J Clin
Oncol. 29:5302011.
|
24.
|
Guarneri V, Frassoldati A, Bottini A, et
al: Final results of a phase II randomized trial of neoadjuvant
anthracycline-taxane chemo-therapy plus lapatinib, trastuzumab, or
both in HER2-positive breast cancer (CHER-LOB trial). J Clin Oncol.
29:5072011.
|
25.
|
Biernat W, Duchnowska R, Szostakiewicz B,
et al: Quantitative measurements of p95HER2 (p95HER2) and total
HER2 (H2T) protein expression in patients with trastuzumab-treated,
metastatic breast cancer (MBC): Independent confirmation of
clinical cutoffs. J Clin Oncol. 29:5862011.
|